Kazbiotech LLP Pharmaceutical Import Profile — Kazakhstan (DGFT 2022–2026)

Name: Kazbiotech LLP Pharmaceutical Import Records from India — 2 Products, $27.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kazbiotech LLP — Pharmaceutical Importer Profile (2026) | 2 Products, $27.1K Trade | TransData Nexus

Kazbiotech LLP

Pharmaceutical Importer · Kazakhstan · Advanced Oncology Focus · $27.1K Total Trade · DGFT Verified

Kazbiotech LLP is a pharmaceutical importer based in Kazakhstan with a total trade value of $27.1K across 2 products in 1 therapeutic categories. Based on 7 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Kazbiotech LLP sources from 11 verified Indian suppliers, with Bharat Serums And Vaccines Limited accounting for 53.4% of imports.

Kazbiotech LLP — Import Portfolio & Supplier Network

Kazbiotech LLP import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Kazbiotech LLP?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bharat Serums And Vaccines Limited	$945.3K	40	53.4%
United Biotech Private Limited	$374.8K	28	21.2%
Saintlife Pharmaceuticals Limited	$185.5K

What Formulations Does Kazbiotech LLP Import?

Formulation	Value	Ships
Thymogam 250MG #[antithymocyte	$247.4K	5
Pharma product-clofazim capsules 100	$125.6K	3
Pharma product-clofazim capsules 100 MG	$59.9K	2
Foligraf 150 IU recombinant #human	$50.0K	1
Foligraf 75 IU#recombinant #human	$50.0K	1
Foligraf 150 IU [recombinant #human	$50.0K	1
Foligraf 75 IU# [recombinant #human	$50.0K	1
Asporelix 0.25 mgcetrorelix acetate forinjection 0.25 MG	$50.0K	1
Thymogam 250MG # antithymocyte globulin- equine	$50.0K	1
Asporelix 0.25 MG (cetrorelix acetate for injection 0.25 MG)	$50.0K	1
Thiotepa injection - IP (lyophilized) with data logger ( pharmaceuticals use ) 100 MG	$50.0K	1
Foligraf 75 IU#recombinant #human follicle stimulating hormone for injection (r-hfsh	$50.0K	1
Pharmaceutical medicinal products lyortam ertapenem sodium for injection 1.0 gmb:ealk4b13 m:11/24	$50.0K	1
Pharmaceutical medicinal products-nimodec,(nimodipine intravenous infusion BP 10MG /50ML)b.niil4a19,m.12/2024	$50.0K	1
Foligraf 75 IU#recombinant #human follicle stimulating hormone for injection (r-hfsh)	$50.0K	1

Kazbiotech LLP imports 86 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Daunorubicin	Advanced Oncology	$18.5K	4	2.7%	6
2	Chlorambucil	Advanced Oncology	$8.6K	3	2.5%	5

Kazbiotech LLP imports 2 pharmaceutical products across 1 categories into Kazakhstan totaling $27.1K.

Kazbiotech LLP — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kazbiotech LLP is a prominent pharmaceutical importer and wholesaler based in Kazakhstan, specializing in the procurement and distribution of finished pharmaceutical formulations. The company is headquartered in Nur-Sultan (formerly Astana), the capital city of Kazakhstan. Established in 2015, Kazbiotech LLP has rapidly positioned itself as a key player in the nation's pharmaceutical supply chain. (pk.adata.kz)

The company operates as an independent entity without a publicly known parent company. Kazbiotech LLP plays a crucial role in ensuring the availability of essential medications across Kazakhstan, particularly in the oncology therapeutic category. By importing a diverse range of pharmaceutical products, the company contributes significantly to the healthcare sector, addressing both common and specialized medical needs.

2Distribution Network

Kazbiotech LLP maintains a centralized distribution model with its primary warehouse located in Nur-Sultan. This strategic location enables efficient logistics and timely delivery of pharmaceutical products throughout Kazakhstan. The company's distribution network is designed to ensure that imported medications reach various regions, including remote areas, thereby enhancing nationwide access to essential drugs.

While the company focuses on domestic distribution, there is no publicly available information indicating expansion beyond Kazakhstan's borders. Kazbiotech LLP's logistics capabilities are tailored to meet the specific demands of the Kazakhstani market, ensuring compliance with local regulations and standards.

3Industry Role

In Kazakhstan's pharmaceutical supply chain, Kazbiotech LLP functions primarily as a pharmaceutical importer and wholesaler. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and distributes them to various healthcare providers, including hospitals, clinics, and pharmacies across the country. This role is vital in bridging the gap between global pharmaceutical manufacturers and the local healthcare system, ensuring the availability of a wide range of medications to meet diverse patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Kazbiotech LLP

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Kazbiotech LLP exhibits a high degree of sourcing concentration, with a total import value of $27,000 USD from India across seven shipments. The company's portfolio is heavily concentrated, with the top five products accounting for 100% of the total import value. This concentration indicates a strategic focus on specific high-demand pharmaceutical products, particularly in the oncology therapeutic category.

The reliance on a limited number of products and suppliers may present risks related to supply chain disruptions or changes in supplier dynamics. However, this focused approach allows Kazbiotech LLP to establish strong relationships with key suppliers, potentially leading to favorable terms and consistent product quality. The stability of these relationships is crucial for maintaining uninterrupted supply and meeting the healthcare needs of the Kazakhstani population.

2Supply Chain Resilience

Kazbiotech LLP's supply chain resilience is closely tied to its sourcing strategy from Indian suppliers. The company's import data reveals partnerships with several Indian pharmaceutical manufacturers, including Bharat Serums and Vaccines Limited, United Biotech Private Limited, and Saintlife Pharmaceuticals Limited. This diversified supplier base suggests a level of risk mitigation against potential disruptions from a single source.

However, the concentration on a narrow range of products and suppliers may limit the company's ability to adapt to sudden market changes or regulatory shifts. To enhance supply chain resilience, Kazbiotech LLP could consider diversifying its product portfolio and establishing relationships with additional suppliers, thereby reducing dependency on specific sources and increasing flexibility in meeting market demands.

Importing Pharmaceuticals into Kazakhstan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kazakhstan

1Regulatory Authority & Framework

The primary regulatory authority overseeing pharmaceutical imports in Kazakhstan is the Ministry of Healthcare of the Republic of Kazakhstan. The legal framework governing the importation of pharmaceutical products is outlined in the Code of the Republic of Kazakhstan on People's Health and Healthcare System, which establishes procedures for the importation, registration, and circulation of medicines and medical devices. (wipolex-res.wipo.int)

Key legislation includes the Rules of Import of Medicines, Medical Devices, and Medical Equipment, which detail the requirements and procedures for importing pharmaceutical products into Kazakhstan. These regulations ensure that imported medicines meet the necessary quality and safety standards before entering the market.

2Import Licensing & GMP

Import licensing in Kazakhstan requires that pharmaceutical products be registered with the Ministry of Healthcare prior to importation. This process involves submitting comprehensive documentation, including evidence of Good Manufacturing Practice (GMP) compliance. Kazakhstan recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of high-quality pharmaceutical products from global manufacturers.

Kazbiotech LLP — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Kazbiotech LLP's strategic focus on importing oncology medications aligns with the growing demand for cancer treatments in Kazakhstan. The company's portfolio includes products like Daunorubicin and Chlorambucil, which are essential in the management of various cancers. This focus addresses critical healthcare needs and positions Kazbiotech LLP as a key supplier of specialized oncology drugs in the region.

The decision to concentrate on oncology products is driven by market demand and the company's expertise in this therapeutic area. By specializing in oncology, Kazbiotech LLP can offer a comprehensive range of treatments, ensuring that patients have access to effective and timely therapies.

2Sourcing Profile

Kazbiotech LLP's sourcing strategy emphasizes the importation of generic drugs, particularly in the oncology category. The company imports finished pharmaceutical formulations, ensuring that products are ready for distribution upon arrival. India serves as a primary source due to its robust pharmaceutical manufacturing sector and adherence to international quality standards. This approach allows Kazbiotech LLP to provide cost-effective and high-quality medications to the Kazakhstani market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Kazbiotech LLP

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Kazbiotech LLP, especially those offering high-quality oncology medications that meet Kazakhstani regulatory standards. Kazbiotech LLP's existing supplier base includes several Indian manufacturers, indicating a preference for sourcing from India. Suppliers that can provide consistent product quality, reliable supply chains, and compliance with GMP standards are well-positioned to enter this market.

Gaps in Kazbiotech LLP's current sourcing may exist in terms of product variety or specific formulations. Suppliers offering innovative oncology treatments or specialized formulations not currently available in Kazakhstan could find a receptive partner in Kazbiotech LLP. Additionally, suppliers that can offer competitive pricing and favorable terms may enhance their attractiveness as potential partners.

2Requirements & Qualifications

Indian exporters seeking to supply Kazbiotech LLP and the broader Kazakhstani market must ensure that their products are

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Kazbiotech LLP

What products does Kazbiotech LLP import from India?

Kazbiotech LLP imports 2 pharmaceutical products across 1 categories. Top imports: Daunorubicin ($18.5K), Chlorambucil ($8.6K).

Who supplies pharmaceuticals to Kazbiotech LLP from India?

Kazbiotech LLP sources from 11 verified Indian suppliers. The primary supplier is Bharat Serums And Vaccines Limited (53.4% of imports, $945.3K).

What is Kazbiotech LLP's total pharmaceutical import value?

Kazbiotech LLP's total pharmaceutical import value from India is $27.1K, based on 7 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Kazbiotech LLP focus on?

Kazbiotech LLP imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Kazbiotech LLP Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.